AMSTERDAM, November 28, 2012 \/PRNewswire\/ -- <\/p>\n
The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in developing countries, finds that the industry is doing more than it was two years ago, with GlaxoSmithKline still outperforming its peers, but an expanding group of leaders closing the gap. <\/p>\n
(Photo: http:\/\/photos.prnewswire.com\/prnh\/20121128\/579726<\/a> )<\/p>\n The Index, published Wednesday, found that Johnson & Johnson was one of the most dramatic risers, climbing from the middle of the field in 9th position in the 2010 Index to 2nd this year, closely behind GlaxoSmithKline. It is one of two newcomers to the top three. Its rise is due largely to its consolidation of its access activities under one business unit, which has resulted in a more strategic and integrated approach, and to its acquisition of vaccine maker Crucell, which has increased the relevance of its research and development investments. It has also disclosed more overall about its access activities. <\/p>\n \"This year's Index shows that companies are becoming more organised internally in their approach to access to medicine and that those who do this best tend to perform well across the other aspects we measure. The leaders are really raising the bar,\" said Wim Leereveld, founder and CEO of the Access to Medicine Index. \"It's also clear that companies that do not continue to step up their efforts tend to be overtaken by their peers.\" <\/p>\n The Access to Medicine Index is an independent initiative that provides insight into what the world's leading pharmaceutical companies are doing for the millions of people in developing countries who do not have reliable access to safe, effective and affordable medicines, vaccines and other health-related technologies. It is published every two years. <\/p>\n It scores companies on their commitments, performance, innovation and level of transparency across seven areas of activity considered key to improving access to medicine. The companies are graded on more than 100 factors covering these areas, including whether they are developing new drugs for neglected diseases, to what extent they facilitate or resist efforts to create generic versions of their drugs, and how they approach pricing in developing countries. Lobbying activities, marketing ethics and product donations and other philanthropic activities are also tracked. <\/p>\n Ranking highlights: Who is doing the most? <\/p>\n GlaxoSmithKline remains at the top of the Index with a marginal improvement in performance since 2010, and this year, Johnson & Johnson and Sanofi, both new to the top three, follow closely in 2nd and 3rd positions respectively. The companies that rose in rank the most were Merck KGaA, followed by Johnson & Johnson, and then Bayer. AstraZeneca fell down the rankings most significantly, followed by Boehringer-Ingelheim, then Novartis and Roche. The bottom of the league is dominated by Japanese companies Takeda, Daiichi and Astellas. <\/p>\n Overall trends <\/p>\n<\/p>\n The rest is here:<\/p>\n Report Finds Big Pharma is Doing More for Access to Medicine in Developing Countries than Two Years Ago<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" AMSTERDAM, November 28, 2012 \/PRNewswire\/ -- The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in developing countries, finds that the industry is doing more than it was two years ago, with GlaxoSmithKline still outperforming its peers, but an expanding group of leaders closing the gap. (Photo: http:\/\/photos.prnewswire.com\/prnh\/20121128\/579726<\/a> ) The Index, published Wednesday, found that Johnson & Johnson was one of the most dramatic risers, climbing from the middle of the field in 9th position in the 2010 Index to 2nd this year, closely behind GlaxoSmithKline. It is one of two newcomers to the top three. Continue reading